Welcome to our dedicated page for Thiogenesis news (Ticker: TTIPF), a resource for investors and traders seeking the latest updates and insights on Thiogenesis stock.
Thiogenesis Therapeutics, Corp. (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company developing sulfur-containing and thiol-based prodrugs for serious pediatric and inherited diseases, particularly rare mitochondrial and metabolic disorders. The Thiogenesis news stream highlights how its lead candidate, TTI-0102, progresses through clinical development and regulatory interactions.
News releases from the company focus heavily on clinical milestones for TTI-0102. These include updates on its randomized, double-blind, placebo-controlled Phase 2 trial in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) in Europe, interim analyses describing biomarker activity and biological proof-of-concept, and activation of additional European trial sites. Thiogenesis also reports on plans and regulatory clearances for a Phase 2a trial in Leigh syndrome spectrum in the United States, as well as preparations for a Phase 3 pivotal trial in nephropathic cystinosis and a Phase 2 or Phase 2a trial in pediatric Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Investors and observers can use the TTIPF news page to follow announcements about scientific presentations at mitochondrial disease conferences, late-breaking abstract acceptances, and participation in webinars and panel discussions organized by patient advocacy and research organizations. Corporate updates such as private placements, stock option grants, investor relations agreements, and patent developments related to asymmetric disulfide prodrugs of cysteamine are also reflected in the news flow.
By reviewing Thiogenesis Therapeutics news, readers gain insight into the timing and design of its clinical trials, the company’s focus on mitochondrial oxidative stress and thiol biology, and the regulatory guidance it receives in key jurisdictions. The news page can be revisited regularly to see how the TTIPF development pipeline and corporate strategy evolve over time based on company disclosures.
Thiogenesis Therapeutics (TSXV: TTI) announces the allowance of a core patent by the European Patent Office titled 'Methods For The Treatment of Cysteamine Sensitive Disorders' (European Patent No. 18858763.8). This patent, set to expire in September 2037, adds to the company's existing patents in the same family granted in the United States (2021) and Japan (2023). The company develops novel thiol compounds, including cysteamine precursors, targeting mitochondrial diseases and related metabolic conditions through their antioxidant and anti-inflammatory properties.